Charles McWherter is President at CymaBay Therapeutics, Inc. (CBAY). They have made 14 open-market trades across 2 companies since 2015, most recently 2025-10-30.
CIK 0001588862
6 open-market purchases totalling $272K since 2015, against 8 sales. Across 6 scored buys the stock is down 1.5% at ninety days, and 0.3 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 33% | 33% |
| Avg Move | +2.0% | +2.4% | -1.5% |
| Alpha | +4.1% | +3.6% | +0.3% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ETNB | BUY | 2025-01-21 | 2025-01-23 | $6.66 | $100K | +50.8% | +42.1% | -7.2% |
| ETNB | BUY | 2024-12-05 | 2024-12-09 | $8.00 | $80K | -13.5% | -9.6% | -12.1% |
| CBAY | SELL · 10b5-1 | 2024-01-19 | 2024-01-22 | $23.67 | $752K | +1.6% | +34.1% | N/A |
| CBAY | SELL | 2023-12-18 | 2023-12-18 | $21.48 | $487K | +2.9% | +4.6% | +41.4% |
| CBAY | SELL | 2023-11-17 | 2023-11-17 | $18.28 | $415K | +4.2% | +23.3% | +75.4% |
| CBAY | SELL | 2023-10-18 | 2023-10-18 | $14.07 | $612K | +20.1% | +34.5% | +77.5% |
| CBAY | SELL | 2023-09-18 | 2023-09-19 | $16.22 | $705K | -4.1% | -14.8% | +45.6% |
| CBAY | SELL | 2023-08-18 | 2023-08-18 | $11.47 | $499K | +15.4% | +33.6% | +52.3% |
| CBAY | SELL | 2023-07-18 | 2023-07-19 | $11.43 | $497K | +10.8% | +0.8% | +21.8% |
| CBAY | SELL | 2023-06-20 | 2023-06-21 | $8.16 | $355K | +39.0% | +37.5% | +83.0% |
| CBAY | SELL | 2023-05-18 | 2023-05-19 | $9.08 | $395K | +2.5% | -7.3% | +27.8% |
| CBAY | BUY | 2017-11-02 | 2017-11-06 | $8.67 | $43K | -1.3% | -4.8% | +33.3% |
| CBAY | BUY | 2017-07-20 | 2017-07-24 | $7.43 | $37K | -11.5% | -20.4% | -2.7% |
| CBAY | BUY | 2016-04-15 | 2016-04-19 | $1.68 | $5K | +11.1% | -1.7% | -29.4% |
| CBAY | BUY | 2015-05-15 | 2015-05-19 | $3.16 | $6K | -23.4% | +9.0% | +9.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.